Drug Drought

Herper, Matthew
October 2007
Forbes Asia;10/29/2007, Vol. 3 Issue 18, p56
The article focuses on Pfizer's drug development efforts. Since 1998, Pfizer has spent $55 billion on research and development and another $180 billion on acquisitions. Yet in that time only nine medicines from its labs have hit the market, and only one, the pain drug Lyrica, has passed $1 billion in annual sales. At one point Pfizer had three of the world's ten top sellers, namely Lipitor for cholesterol, Norvasc for blood pressure and Zoloft for depression.


Related Articles

  • Pharma Deals North of $10 Billion Seen Returning in 2013.  // MondayMorning;1/14/2013, Vol. 21 Issue 1, p1 

    The article reports the business planning of several companies including Pfizer Inc., Bristol-Myers Squibb Co. and Abbott Laboratories Inc. regarding mergers and acquisitions activity in the year 2013. It mentions that most of these companies have gathered funds and are focusing to improve their...

  • Gateway For New Medicines. Katz, Jonathan // Industry Week/IW;May2006, Vol. 255 Issue 5, p52 

    Analyzes a decision by New York-base Pfizer Inc. to maintain research operations in Saint Louis, Missouri after acquiring Pharmacia Corp., as of May 2006. Reasons behind the decision; Background on the construction of a research building by Pfizer in Saint Louis that will consolidate research...

  • Ireland: Pharma's market. Harris, Joanne // Lawyer;9/23/2013, p1 

    The article focuses on the pharmaceutical sector within Ireland in 2013. Topics include the merger and acquisition of pharmaceutical companies in the country, the presence of large pharmaceutical companies such as GlaxoSmithKline and Pfizer in Ireland, and the use of research and development...

  • HEALTHCARE. Clark, Scott // PRWeek (London);Jun2014, p21 

    The article presents the author's views on the requirement of communications industry in the merger of pharmaceutical companies Pfizer and AstraZeneca. According to him, the merger deal was focused on the research and development (R&D) technique of company and on the importance of scientific...

  • ATTACK OF THE MONSTER MERGER. Armstrong, Walter // Pharmaceutical Executive;Mar2009, Vol. 29 Issue 3, p36 

    The article reports on the concerns over the merger between Pfizer Inc. and Wyeth. The American Antitrust Institute argues that there is scant reason to believe that the merger would improve research and development (R&D) and it would make Pfizer's bureaucratic situation worse. However, Goldman...

  • 2004 Round-Up: 'Twas the Best of Times -- 'Twas the Worst of Times.  // BioPharm International;Dec2004, Vol. 17 Issue 12, p12 

    The article presents information on the best and the worst events that happened in pharmaceutical industry in the year 2004. While the overall stock market struggled in 2004, held back by uncertainty over the War in Iraq, the presidential elections, and the plummeting dollar, the Nasdaq Biotech...

  • The Cents and Nonsense of Pfizer Buying Wyeth. Thiel, Karl // BioWorld Today;2/2/2009, Vol. 20 Issue 20, p1 

    The article examines Pfizer's $68 billion bid to buy out Wyeth. It is indicated that Wyeth makes the majority of its revenue from nontraditional drug products, such as biologics and vaccines. The article speculates that Effexor, Wyeth's biggest product, will see sales erode in the face of...

  • Pfizer Picking Up FoldRx in Latest Rare Disease Buyout. Boggs, Jennifer // BioWorld Today;9/2/2010, Vol. 21 Issue 170, p1 

    The article reports on the plan of Pfizer Inc. to acquire privately-held FoldRX Pharmaceuticals Inc. The takeover is part of the plan of Pfizer to increase its presence in the rare disease market as FoldRX has a drug for rare neurodegenerative disease transthyretin amyloid polyneuropathy...

  • COMPANY CV.  // Marketing (00253650);2/12/2004, p50 

    A Pharmaceuticals group Pfizer Inc. operates two divisions. The first produces prescription drugs to treat cardiovascular diseases, infectious diseases, central nervous system disorders, diabetes, erectile dysfunction, allergies, arthritis and other disorders. The second manufactures medications...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics